CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.
Animals
Antigens, CD
/ genetics
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Aptamers, Nucleotide
/ pharmacology
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Disease Models, Animal
Doxorubicin
/ analogs & derivatives
Drug Synergism
Female
Humans
Mice
Mice, Inbred BALB C
Mice, Knockout
Orexin Receptors
/ genetics
Polyethylene Glycols
/ pharmacology
Aptamer
Breast cancer
CD200
Doxorubicin
MDSC
Metastasis
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
06
03
2019
accepted:
27
11
2019
pubmed:
8
12
2019
medline:
15
2
2020
entrez:
8
12
2019
Statut:
ppublish
Résumé
We previously reported that CD200 overexpression in the host decreases progression and metastasis of the highly aggressive metastatic 4THM breast carcinoma. We have explored a possible synergistic interaction between the CD200 mimetic PEG-M49 and pegylated liposomal doxorubicin (Peg-Dox) in wild-type CD200 knockout (CD200
Identifiants
pubmed: 31811336
doi: 10.1007/s00262-019-02444-3
pii: 10.1007/s00262-019-02444-3
doi:
Substances chimiques
Antigens, CD
0
Aptamers, Nucleotide
0
Cd200r1 protein, mouse
0
Orexin Receptors
0
liposomal doxorubicin
0
Polyethylene Glycols
3WJQ0SDW1A
Doxorubicin
80168379AG
antigens, CD200
UQ4V77A8VA
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-114Subventions
Organisme : Akdeniz Üniversitesi
ID : TUA-2015-585
Références
Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M et al (2003) Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 171(6):3034–3046
pubmed: 12960329
Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH et al (2000) Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 13(2):233–242
pubmed: 10981966
Erin N, Kale S, Tanriover G, Koksoy S, Duymus O, Korcum AF (2013) Differential characteristics of heart, liver, and brain metastatic subsets of murine breast carcinoma. Breast Cancer Res Treat 139(3):677–689
pubmed: 23760857
Erin N, Podnos A, Tanriover G, Duymus O, Cote E, Khatri I et al (2015) Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene 34(29):3860–3870
pubmed: 25263452
Gorczynski RM, Chen Z, He W, Khatri I, Sun Y, Yu K et al (2009) Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 183(3):1560–1568
pubmed: 19592654
Erin N, Tanriover G, Curry A, Akman M, Duymus O, Gorczynski R (2018) CD200fc enhances anti-tumoral immune response and inhibits visceral metastasis of breast carcinoma. Oncotarget 9(27):19147–19158
pubmed: 29721190
pmcid: 5922384
Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden PA (2004) CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol 172(12):7744–7749
pubmed: 15187158
Gorczynski R, Boudakov I, Khatri I (2008) A comparison of the biological properties of small molecular weight agonists and antagonists of CD200: CD200R interactions. Med Chem 4(6):624–631
pubmed: 18991748
Gorczynski R, Boudakov I, Khatri I (2008) Peptides of CD200 modulate LPS-induced TNF-alpha induction and mortality in vivo. J Surg Res 145(1):87–96
pubmed: 17981299
Kuwabara J, Umakoshi A, Abe N, Sumida Y, Ohsumi S, Usa E et al (2018) Truncated CD200 stimulates tumor immunity leading to fewer lung metastases in a novel Wistar rat metastasis model. Biochem Biophys Res Commun 496(2):542–548
pubmed: 29339155
Gilboa E, McNamara J, Pastor F (2013) Use of oligonucleotide aptamer ligands to modulate the function of immune receptors. Clin Cancer Res 19(5):1054–1062
pubmed: 23460536
Da PC, Blackshaw E, Missailidis S, Perkins AC (2012) PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice. Bioconjug Chem 23(7):1377–1381
Prodeus A, Cydzik M, Abdul-Wahid A, Huang E, Khatri I, Gorczynski R et al (2014) Agonistic CD200R1 DNA aptamers are potent immunosuppressants that prolong allogeneic skin graft survival. Mol Ther Nucleic Acids 3:e190
pubmed: 25158092
pmcid: 4221601
Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65(2):157–170
pubmed: 23278683
Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT et al (2010) Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 5(4):e10365
pubmed: 20442777
pmcid: 2860989
Panis C, Lemos LG, Victorino VJ, Herrera AC, Campos FC, Colado Simao AN et al (2012) Immunological effects of taxol and adryamicin in breast cancer patients. Cancer Immunol Immunother 61(4):481–488
pubmed: 21959683
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202(12):1691–1701
pubmed: 16365148
pmcid: 2212968
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61
pubmed: 17187072
Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B et al (2014) Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res 74(1):104–118
pubmed: 24197130
Erin N, Akdas BG, Harms JF, Clawson GA (2008) Vagotomy enhances experimental metastases of 4THMpc breast cancer cells and alters substance P level. Regul Pept 151(1–3):35–42
pubmed: 18499282
Boudakov I, Liu J, Fan N, Gulay P, Wong K, Gorczynski RM (2007) Mice lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-alpha and mixed leukocyte culture responses by CD200. Transplantation 84(2):251–257
pubmed: 17667818
Gorczynski RM, Chen Z, Diao J, Khatri I, Wong K, Yu K et al (2010) Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 123(2):405–415
pubmed: 19953316
Ryckman C, McColl SR, Vandal K et al (2003) Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum 48(8):2310–2320
pubmed: 12905486
Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA et al (2013) Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol 15(7):891–903
pubmed: 23595625
pmcid: 3688013
Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174(2):636–645
pubmed: 15634881
Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117(12):3988–4002
pubmed: 18060036
pmcid: 2096439
Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693–706
pubmed: 19878981
pmcid: 2783826
Storci G, Sansone P, Mari S, D’Uva G, Tavolari S, Guarnieri T et al (2010) TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol 225(3):682–691
pubmed: 20509143
pmcid: 2939957
Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG et al (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19(6):715–727
pubmed: 21665146
pmcid: 3144144
Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA (2003) Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol 170(6):3233–3242
pubmed: 12626582
Gorczynski RM, Cattral MS, Chen Z, Hu J, Lei J, Min WP et al (1999) An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 163(3):1654–1660
pubmed: 10415071
Ren Y, Ye M, Chen S, Ding J (2016) CD200 inhibits inflammatory response by promoting KATP channel opening in microglia cells in Parkinson’s disease. Med Sci Monit 22:1733–1741
pubmed: 27213506
pmcid: 4917312
Ling MY, Ma ZY, Wang YY, Qi J, Liu L, Li L et al (2013) Up-regulated ATP-sensitive potassium channels play a role in increased inflammation and plaque vulnerability in macrophages. Atherosclerosis 226(2):348–355
pubmed: 23218803
Chen Z, Yu K, Zhu F, Gorczynski R (2016) Over-expression of CD200 protects mice from dextran sodium sulfate induced colitis. PLoS One 11(2):e0146681
pubmed: 26841120
pmcid: 4740450
Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W et al (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108(41):17111–17116
pubmed: 21969559
pmcid: 3193202
Desfrancois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, Dreno B et al (2010) Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. PLoS One 5(1):e8437
pubmed: 20052413
pmcid: 2797605
Parel Y, Aurrand-Lions M, Scheja A, Dayer JM, Roosnek E, Chizzolini C (2007) Presence of CD4 + CD8 + double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 56(10):3459–3467
pubmed: 17907151
Desfrancois J, Derre L, Corvaisier M, Le MB, Catros V, Jotereau F et al (2009) Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions. Int J Cancer 125(2):374–380
pubmed: 19358272
Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B (2004) Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood 104(2):478–486
pubmed: 15044252
Frahm MA, Picking RA, Kuruc JD, McGee KS, Gay CL, Eron JJ et al (2012) CD4 + CD8 + T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol 188(9):4289–4296
pubmed: 22461689
Suni MA, Ghanekar SA, Houck DW, Maecker HT, Wormsley SB, Picker LJ et al (2001) CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur J Immunol 31(8):2512–2520
pubmed: 11500836
Hirao J, Sugita K (1998) Circulating CD4 + CD8 + T lymphocytes in patients with Kawasaki disease. Clin Exp Immunol 111(2):397–401
pubmed: 9486410
pmcid: 1904915